Compare Kimberly Clark Corp (KMB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs 10X Genomics Inc — how do they compare? Kimberly Clark Corp trades at $97.99 (market cap $32.51B), while 10X Genomics Inc trades at $80.87 (market cap $10.07B). The key difference: Kimberly Clark Corp is far larger — about 3.2× 10X Genomics Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and 10X Genomics Inc for 91 Days on average.
| KMB | TXG | |
|---|---|---|
Market Cap | $32.51B | $10.07B |
Volume | 6,139,913 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $97.74 |
52-Week Low | $93.05 | $11.48 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $38.07B | $9.59B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.59, up 1.15% on the day, but remains in a bearish technical trend. The stock has shown mixed earnings performance, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue declining to $16.45 billion in 2025. The company maintains a strong dividend history, recently declaring a $1.28 payout, while navigating its pending acquisition of Kenvue and executive transitions.
KMB offers a high dividend yield near 5%, supported by 54 consecutive years of increases, but faces risks from the Kenvue integration and cash flow pressures. Analyst consensus is a 'Hold' with a $117.25 price target, suggesting moderate upside. Key risks include execution of the large acquisition and sustaining dividend payouts amid fluctuating cash flows.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
